Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Denosumab Treatment of Severe Disuse Osteoporosis in a Boy With Spinal Muscular Atrophy

S. Kutilek,

. 2017 ; 55 (10) : 658-660.

Jazyk angličtina Země Írán

Typ dokumentu kazuistiky, časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc18024440

Denosumab is a fully human recombinant monoclonal antibody to the receptor activator of nuclear factor-κB ligand. Denosumab is used in the treatment of postmenopausal osteoporosis and cancer-related bone disorders. There are only very scarce data on denosumab treatment in children. 14-year-old boy with spinal muscular atrophy (SMA) and severe disuse osteoporosis (spinal bone mineral density L1-L4 BMD-6.2SD Z-score) and two prevalent fragility fractures was treated with denosumab. He received 60 mg  subcutaneous injection at the baseline and seven months later. Six months after the initial injection there was a 19% increase in L1-L4 BMD. The injections were well tolerated without any adverse reactions. Calcemia remained stable (2.3-2.4 mmol/L). He was scheduled for the third denosumab injection six months later. Prior to this date, he acquired pneumonia and died due to respiratory failure, which is a frequent cause of death in patients with SMA. There was no relation to the denosumab treatment. In conclusion, one dose of denosumab significantly increased BMD in a child with severe osteoporosis.

000      
00000naa a2200000 a 4500
001      
bmc18024440
003      
CZ-PrNML
005      
20181113094552.0
007      
ta
008      
180709s2017 ir f 000 0|eng||
009      
AR
035    __
$a (PubMed)29228533
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a ir
100    1_
$a Kutilek, Stepan $u Department of Pediatrics, Pardubice Hospital, Pardubice, Czech Republic.
245    10
$a Denosumab Treatment of Severe Disuse Osteoporosis in a Boy With Spinal Muscular Atrophy / $c S. Kutilek,
520    9_
$a Denosumab is a fully human recombinant monoclonal antibody to the receptor activator of nuclear factor-κB ligand. Denosumab is used in the treatment of postmenopausal osteoporosis and cancer-related bone disorders. There are only very scarce data on denosumab treatment in children. 14-year-old boy with spinal muscular atrophy (SMA) and severe disuse osteoporosis (spinal bone mineral density L1-L4 BMD-6.2SD Z-score) and two prevalent fragility fractures was treated with denosumab. He received 60 mg  subcutaneous injection at the baseline and seven months later. Six months after the initial injection there was a 19% increase in L1-L4 BMD. The injections were well tolerated without any adverse reactions. Calcemia remained stable (2.3-2.4 mmol/L). He was scheduled for the third denosumab injection six months later. Prior to this date, he acquired pneumonia and died due to respiratory failure, which is a frequent cause of death in patients with SMA. There was no relation to the denosumab treatment. In conclusion, one dose of denosumab significantly increased BMD in a child with severe osteoporosis.
650    _2
$a mladiství $7 D000293
650    _2
$a kostní denzita $x účinky léků $7 D015519
650    _2
$a inhibitory kostní resorpce $x terapeutické užití $7 D050071
650    _2
$a denosumab $x terapeutické užití $7 D000069448
650    _2
$a fraktury kostí $x farmakoterapie $7 D050723
650    _2
$a lidé $7 D006801
650    _2
$a injekce subkutánní $7 D007279
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a spinální svalová atrofie $x komplikace $7 D009134
650    _2
$a osteoporóza $x farmakoterapie $7 D010024
655    _2
$a kazuistiky $7 D002363
655    _2
$a časopisecké články $7 D016428
773    0_
$w MED00000071 $t Acta medica Iranica $x 1735-9694 $g Roč. 55, č. 10 (2017), s. 658-660
856    41
$u https://pubmed.ncbi.nlm.nih.gov/29228533 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20180709 $b ABA008
991    __
$a 20181113094637 $b ABA008
999    __
$a ok $b bmc $g 1316571 $s 1021361
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2017 $b 55 $c 10 $d 658-660 $i 1735-9694 $m Acta medica iranica $n Acta Med Iran $x MED00000071
LZP    __
$a Pubmed-20180709

Najít záznam

Citační ukazatele

Nahrávání dat ...

Možnosti archivace

Nahrávání dat ...